Wegovy EPAR product information (PDF)
Beyond clinical data, acupunctures rationale is grounded in TCM theory, which conceptualises HT as a disorder of spleen and kidney yang deficiency or liver qi stagnation leading to phlegm obstruction. These imbalances are thought to disrupt the bodys internal harmony and immune defence
Participants adherent to tirzepatide treatment and achieving 5% weight loss by primary endpoint (week 72 SURMOUNT1
Ribupatide: Dual GLP-1/GIP receptor agonist peptide
The primary outcome measures clinical remission using mMS at 12 weeks, while secondary endpoints include endoscopic remission, clinical response, and safety parameters, with the study having started in December 2024 and estimated completion in June 2028 across 52 locations in the US and Europe
Before treatment Before treatment I was skeptical about starting a prescription weight loss medication but it has exceeded my expectations